Stephanie DeArmey

The emerging phenotype of long-term survivors with infantile Pompe disease

Sean N. Prater, Suhrad G. Banugaria, Stephanie DeArmey et al. · Genetics in Medicine · 2012 · 187 citations · Full text

Infantile Pompe Disease, Pathogenesis, Genetic Epidemiology +3

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Benedikt Schoser, Mark Roberts, Barry J. Byrne et al. · The Lancet Neurology · 2021 · 124 citations

Clinical Trials, Cipaglucosidase Alfa, Pharmacotherapy +2

Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT

Suhrad G. Banugaria, Sean N. Prater, Trusha Patel et al. · PLoS ONE · 2013 · 110 citations · Full text

Cardiac arrhythmias following anesthesia induction in infantile‐onset Pompe disease: a case series

LUKE Y.‐J. WANG, Allison Kinder Ross, Jennifer S. Li et al. · Pediatric Anesthesia · 2007 · 59 citations

Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease

Laura E. Case, Carl Bjartmar, Claire Morgan et al. · Neuromuscular Disorders · 2014 · 58 citations · Full text

Pompe Disease, Translational Medicine, Autoimmune Disease +4